low dose of octreotide can be helpful in the management of congenital chylothorax
نویسندگان
چکیده
conclusions octreotide therapy as one of the conservative managements for cc can be considered before surgical methods. this treatment method also had some effects on the feeding initiation time and helped us to start feeding sooner. however, more studies like clinical trials are still necessary to investigate all aspects of octreotide treatment to determine the amount of its dose, initiation time, treatment duration, etc. case presentation a 3100-g-term male newborn delivered vaginally from a 33-year-old mother was admitted to the neonatal intensive care unit with respiratory distress signs. early chest x-ray (cxr) showed bilateral pleural effusion. the thoracentesis pleural fluid had been drained with these characteristics: glucose: 1.9425 mmol/l, protein: 11 g/l, cholesterol: 1.295 mmol/l, and triglycerides: 3.39 mmol/l. counts of red blood cells and white blood cells were 10,000 and 2500 per cu/mm, respectively; so, congenital chylothorax was diagnosed and total parenteral nutrition (tpn) were initiated. accumulation of plural fluid was approximately stopped after begging tpn for two weeks. therefore, we started feeding with a medium chain triglyceride (mct), but plural effusion was seen once again and we had to restart tpn. we decided to start octreotide subcutaneously (1 μg/kg/day). finally, the cxr and ultrasound ’did not show any pleural effusion in both sides and the ultrasound done in the third month showed no pleural effusion either. introduction a rare condition in newborns called congenital chylothorax (cc) occurs when lymphatic fluid accumulates within the pleural cavity. here is a presentation of a birth traumatic case with bilateral pleural effusion successfully treated by octreotide.
منابع مشابه
Low Dose of Octreotide Can be Helpful in the Management of Congenital Chylothorax
INTRODUCTION A rare condition in newborns called congenital chylothorax (CC) occurs when lymphatic fluid accumulates within the pleural cavity. Here is a presentation of a birth traumatic case with bilateral pleural effusion successfully treated by octreotide. CASE PRESENTATION A 3100-g-term male newborn delivered vaginally from a 33-year-old mother was admitted to the neonatal intensive care...
متن کاملOctreotide for the Management of Chylothorax in newborns, case report
Chylothorax is the most common cause of pleural effusion in neonates. It is usually idiopathic. Neonatal chylothorax successfully respond to octreotide treatment and can reduce the duration of hospitalization. A number of therapeutic interventions have been used to reduce chyle production and promote resolution of a chylothorax. Initial management typically includes restriction or temporary ces...
متن کاملoctreotide for the management of chylothorax in newborns, case report
chylothorax is the most common cause of pleural effusion in neonates. it is usually idiopathic. neonatal chylothorax successfully respond to octreotide treatment and can reduce the duration of hospitalization. a number of therapeutic interventions have been used to reduce chyle production and promote resolution of a chylothorax. initial management typically includes restriction or temporary ces...
متن کاملThe use of octreotide to treat congenital chylothorax.
We report the use of the octreotide (a somatostatin analogue) in the treatment of idiopathic congenital chylothorax in a patient with Turner's syndrome who had previously failed conservative medical therapy. The patient improved rapidly after initiation of octreotide with complete resolution after 5 days of continuous therapy (10 microg/kg per hour).
متن کاملEffects of somatostatin/octreotide treatment in neonates with congenital chylothorax
The influence of somatostatin/octreotide treatment on outcomes of neonates with congenital chylothorax remains controversial. We retrospectively reviewed our experience with somatostatin/octreotide therapy in neonates with this very rare disease.Fourteen neonates with congenital chylothorax who were treated with somatostatin (3.5-7 μg/kg/h, before 2016) or octreotide (1-6 μg/kg/h, after January...
متن کاملمنابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
iranian red crescent medical journalجلد ۱۷، شماره ۱۰، صفحات ۰-۰
کلمات کلیدی
میزبانی شده توسط پلتفرم ابری doprax.com
copyright © 2015-2023